

Mini-review on CRISPR-Cas9 and its potential applications to help controlling neglected tropical diseases caused by Trypanosomatidae

Cécile Minet, Sophie Thevenon, Isabelle Chantal, Philippe Solano, David Berthier

PII: S1567-1348(18)30075-3
DOI: doi:10.1016/j.meegid.2018.02.030
Reference: MEEGID 3431

To appear in: *Infection, Genetics and Evolution*

Received date: 27 November 2017
Revised date: 19 February 2018
Accepted date: 22 February 2018

Please cite this article as: Cécile Minet, Sophie Thevenon, Isabelle Chantal, Philippe Solano, David Berthier , Mini-review on CRISPR-Cas9 and its potential applications to help controlling neglected tropical diseases caused by Trypanosomatidae. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Meegid(2017), doi:10.1016/j.meegid.2018.02.030

Title:

Mini-review on CRISPR-Cas9 and its potential applications to help controlling neglected tropical diseases caused by Trypanosomatidae

Authors:

Cécile MINET [a,c,*]; a: CIRAD, UMR INTERTRYP, F-34398 Montpellier, France. c: INTERTRYP, Univ Montpellier, CIRAD, IRD, Montpellier, France; cecile.minet@cirad.fr

Sophie THEVENON [a,c]; a: CIRAD, UMR INTERTRYP, F-34398 Montpellier, France. c: INTERTRYP, Univ Montpellier, CIRAD, IRD, Montpellier, France; sophie.thevenon@cirad.fr

Isabelle CHANTAL [a,c]; a: CIRAD, UMR INTERTRYP, F-34398 Montpellier, France. c: INTERTRYP, Univ Montpellier, CIRAD, IRD, Montpellier, France; isabelle.chantal@cirad.fr

Philippe SOLANO [b]; b : IRD, UMR INTERTRYP IRD, CIRAD, University of Montpellier, F-34398 Montpellier, France ; philippe.solano@ird.fr

David BERTHIER [a,c]; a: CIRAD, UMR INTERTRYP, F-34398 Montpellier, France. c: INTERTRYP, Univ Montpellier, CIRAD, IRD, Montpellier, France; david.berthier@cirad.fr

Corresponding author:

Cécile MINET [a,c]; a: CIRAD, UMR INTERTRYP, F-34398 Montpellier, France. c: INTERTRYP, Univ Montpellier, CIRAD, IRD, Montpellier, France; cecile.minet@cirad.fr

Abstract

The CRISPR-Cas system, which was originally identified as a prokaryotic defense mechanism, is increasingly being used for the functional study of genes. This technology, which is simple, inexpensive and efficient, has aroused a lot of enthusiasm in the scientific community since its discovery, and every month many publications emanate from very different communities reporting on the use of CRISPR-Cas9. Currently, there are no vaccines